

(iodo)Phe-Pro-His-(iodo)Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val (SEQ ID NO: 37),
Cys-Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Cys (SEQ ID NO: 2), and
Asp-Ala-Leu-Thr-Asn-Ala-Val-Ala-His-Val-Asp-Met-Pro-Asn-Als-Leu-Ser-Ala (SEQ ID NO: 3).

Claim 85, line 3, after "Lys", insert --(SEQ ID NO: 35)--; and

line 4, after "Pro", insert --(SEQ ID NO: 36)--.

Claim 88, line 9, after "Val", insert --(SEQ ID NO: 1)--;

line 10, after "Cys" (second occurrence), insert --(SEQ ID NO: 2)--; and

line 11, after "Ala" (fifth occurrence), insert --(SEQ ID NO: 3)--.

Claim 89, line 9, after "Val", insert --(SEQ ID NO: 1)--;

line 10, after "Cys" (second occurrence), insert --(SEQ ID NO: 2)--; and

line 11, after "Ala" (fifth occurrence), insert --(SEQ ID NO: 3)--.

REMARKS

Reconsideration is requested.

In accordance with 37 CFR 1.825(a), it is noted that support for the amendments are found throughout the specification and the substitute sheets containing the Sequence Listing include no new matter.

sequence identifies as required by the Notice to Comply (copy attached).

The Examiner has requested a substitute claim 47 as the originally claim is apparently unreadable in the Patent Office copy of the application. The applicants note claim 47 should read as follows


“47. A method of stimulating stem cell proliferation comprising
contacting hematopoietic cells with a stem cell proliferation stimulating
amount of INPROL and/or an opiate compound.”

As the applicants are not aware of the portion of the claim which is missing in the Patent Office copy of the application, it is not clear how the claim should be amended in the above and the quotation of the claim in this paragraph is submitted to aid the Examiner in response to ¶ 3 of Paper No. 11. The Examiner is invited to contact the undersigned if anything further is required in this regard.

In view of the above and attached, the present application is submitted to be in compliance with the rules relating to Sequence Listings and an early and favorable Action on the merits is requested. The Examiner is invited to contact the undersigned if anything further is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4091
Facsimile: (703) 816-1170

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. Other: *Applicant has not identified the peptide sequences in the claims with SEQ ID NO.s.*
Applicant must provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For Rules interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.